Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flurbiprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.97 |
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.97 |
| ▸ | AKR1C3 | P42330 | 11/20 | 0.97 |
| ▸ | AKR1C2 | P52895 | 11/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.97 |
| ▸ | MEN1 | O00255 | 2/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | FABP2 | P12104 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.97 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.97 |
| ▸ | HTR2C | P28335 | 1/20 | 0.97 |
| ▸ | DRD3 | P35462 | 1/20 | 0.97 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.97 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Esflurbiprofen SCHEMBL12505766 | 1.00 | AKR1C3 (0.97) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Tarenflurbil SCHEMBL29350102 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Esflurbiprofen SCHEMBL505817 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL1070292 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8754830 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL10029029 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8754978 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8755275 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Tarenflurbil SCHEMBL26131 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL2248 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107445818-B | Cisplatin-flurbiprofen prodrug and preparation method and application thereof | 国家纳米科学中心 | 2020-08-11 | — | — | CN | claimed |
| CN-107445818-B | Cisplatin-flurbiprofen prodrug and preparation method and application thereof | 国家纳米科学中心 | 2020-08-11 | — | — | CN | disclosed |
| EP-2588462-B1 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA | GALDERMA RES & DEV (FR) | 2014-08-13 | — | — | EP | disclosed |
| US-8802710-B2 | Metronidazole esters for treating rosacea | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20130217740-A1 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-08-22 | — | — | US | disclosed |
| EP-2588462-A1 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA | Galderma Research & Development (FR) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012001053-A1 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-01-05 | — | — | WO | disclosed |
| US-5036157-A | Hydroxamic acid derivatives, lipoxygenase and cyclooxygenase inhibitors, anticoagulants, antiinflammatory agents | BURROUGHS WELLCOME CO. | 1991-07-30 | — | — | US | disclosed |
| US-4977188-A | Hydroamic acid derivatives | BURROUGHS WELLCOME CO. (US) | 1990-12-11 | — | — | US | disclosed |
| WO-1990001929-A1 | NEW MEDICAL USE | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-03-08 | — | — | WO | disclosed |
| US-4738986-A | CYCLOOXYGENASE, LIDOXYGENASE INHIBITORS | BURROUGHS WELLCOME CO. (US) | 1988-04-19 | — | — | US | disclosed |
| EP-0196184-A2 | Aryl derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217740-A1 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA | CYP2C19, MDH2, CYP2E1 | PTGS1 871/4885PTGS2 888/4885AKR1C3 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.